Kite Reports Fourth Quarter and Full Year 2016 Financial Results
Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016
On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017
Potential U.S. Approval and Launch of Axicabtagene Ciloleucel Expected in 2017
Conference Call to Be Held Today at 9:00 AM Eastern Time
SANTA MONICA, Calif. -- Kite Pharma, Inc. (Nasdaq:KITE) today provided a corporate update and reported fourth quarter and full-year 2016 financial results for the period ended December 31, 2016.
- Published: 28 February 2017
- Written by Editor